E258k HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction

Journal of General Physiology

Volumn 142, Issue 3, 2013, Pages 241-255

  De Lange, Willem J ^a   Grimes, Adrian C ^a   Hegge, Laura F ^a   Spring, Alexander M ^a   Brost, Taylor M ^a   Ralphe, J Carter ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CARRIER PROTEIN; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; MYOSIN-BINDING PROTEIN C;

ANIMAL; ARTICLE; BINDING SITE; CHEMISTRY; CYTOLOGY; GENETICS; HEART CONTRACTION; HEART MUSCLE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; KINETICS; METABOLISM; MOUSE; MUSCLE STRENGTH; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; SARCOMERE;

ACTINS; ANIMALS; BINDING SITES; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; HUMANS; KINETICS; MICE; MUSCLE STRENGTH; MUTATION; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOSIN HEAVY CHAINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SARCOMERES;

EID: 84883211779     PISSN: 00221295     EISSN: 15407748     Source Type: Journal    
DOI: 10.1085/jgp.201311018     Document Type: Article

References (50)

1. Ababou, A., M. Gautel, and M. Pfuhl. 2007. Dissecting the N-terminal myosin binding site of human cardiac myosin-binding protein C. Structure and myosin binding of domain C2. J. Biol. Chem. 282:9204-9215. http://dx.doi.org/10.1074/jbc.M610899200
2. Ababou, A., E. Rostkova, S. Mistry, C. Le Masurier, M. Gautel, and M. Pfuhl. 2008. Myosin binding protein C positioned to play a key role in regulation of muscle contraction: structure and interactions of domain C1. J. Mol. Biol. 384:615-630. http://dx.doi .org/10.1016/j.jmb.2008.09.065
3. Alders, M., R. Jongbloed, W. Deelen, A. van den Wijngaard, P. Doevendans, F. Ten Cate, V. Regitz-Zagrosek, H.P. Vosberg, I. van Langen, A. Wilde, et al. 2003. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur. Heart J. 24:1848-1853. http://dx.doi.org/10.1016/S0195-668X (03)00466-4
4. Andersen, P.S., O. Havndrup, H. Bundgaard, L.A. Larsen, J. Vuust, A.K. Pedersen, K. Kjeldsen, and M. Christiansen. 2004. Genetic and phenotypic characterization of mutations in myosin- binding protein C(MYBPC3) in 81 families with familial hypertrophic cardiomyopathy: total or partial haploinsufficiency. Eur. J. Hum. Genet. 12:673-677. http://dx.doi.org/10.1038/sj.ejhg.5201190
5. Barefield, D., and S. Sadayappan. 2010. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J. Mol. Cell. Cardiol. 48:866-875. http://dx.doi.org/10.1016/j.yjmcc.2009.11.014
6. Bhuiyan, M.S., J. Gulick, H. Osinska, M. Gupta, and J. Robbins. 2012. Determination of the critical residues responsible for cardiac myosin binding protein C's interactions. J. Mol. Cell. Cardiol. 53:838-847. http://dx.doi.org/10.1016/j.yjmcc.2012.08.028
7. Blankenfeldt, W., N.H. Thomä, J.S. Wray, M. Gautel, and I. Schlichting. 2006. Crystal structures of human cardiac -myosin II S2- provide insight into the functional role of the S2 subfragment. Proc. Natl. Acad. Sci. USA. 103:17713-17717. http://dx.doi.org/10.1073/pnas.0606741103
8. Carrier, L., G. Bonne, E. Bährend, B. Yu, P. Richard, F. Niel, B. Hainque, C. Cruaud, F. Gary, S. Labeit, et al. 1997. Organization and sequence of human cardiac myosin binding protein C gene(MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ. Res. 80:427-434.
9. Colson, B.A., T. Bekyarova, M.R. Locher, D.P. Fitzsimons, T.C. Irving, and R.L. Moss. 2008. Protein kinase A-mediated phosphorylation of cMyBP-C increases proximity of myosin heads to actin inresting myocardium. Circ. Res. 103:244-251. http://dx.doi.org/10.1161/CIRCRESAHA.108.178996
10. Colson, B.A., M.R. Locher, T. Bekyarova, J.R. Patel, D.P. Fitzsimons, T.C. Irving, and R.L. Moss. 2010. Differential roles of regulatory light chain and myosin binding protein-C phosphorylations in the modulation of cardiac force development. J. Physiol. 588:981- 993. http://dx.doi.org/10.1113/jphysiol.2009.183897
11. Colson, B.A., J.R. Patel, P.P. Chen, T. Bekyarova, M.I. Abdalla, C.W. Tong, D.P. Fitzsimons, T.C. Irving, and R.L. Moss. 2012. Myosin binding protein-C phosphorylation is the principal mediator of protein kinase A effects on thick filament structure in myocardium. J. Mol. Cell. Cardiol. 53:609-616. http://dx.doi.org/10.1016/j.yjmcc.2012.07.012
12. Copeland, O., S. Sadayappan, A.E. Messer, G.J. Steinen, J. van der Velden, and S.B. Marston. 2010. Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. J. Mol. Cell. Cardiol. 49:1003-1011. http://dx.doi.org/10.1016/j.yjmcc.2010.09.007
13. de Lange, W.J., L.F. Hegge, A.C. Grimes, C.W. Tong, T.M. Brost, R.L. Moss, and J.C. Ralphe. 2011. Neonatal mouse-derived engineered cardiac tissue: a novel model system for studying genetic heart disease. Circ. Res. 109:8-19. http://dx.doi.org/10.1161/CIRCRESAHA.111.242354
14. de Lange, W.J., A.C. Grimes, L.F. Hegge, and J.C. Ralphe. 2013. Ablation of cardiac myosin-binding protein-C accelerates contractile kinetics in engineered cardiac tissue. J. Gen. Physiol. 141:73-84. http://dx.doi.org/10.1085/jgp.201210837
15. Ehlermann, P., D. Weichenhan, J. Zehelein, H. Steen, R. Pribe, R. Zeller, S. Lehrke, C. Zugck, B.T. Ivandic, and H.A. Katus. 2008. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med. Genet. 9:95. http://dx.doi.org/10.1186/1471-2350-9-95
16. Fananapazir, L., and S.E. Epstein. 1991. Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone. Am. J. Cardiol. 67:175-182. http://dx.doi.org/10.1016/0002-9149(91)90441-M
17. Fraysse, B., F. Weinberger, S.C. Bardswell, F. Cuello, N. Vignier, B. Geertz, J. Starbatty, E. Krämer, C. Coirault, T. Eschenhagen, et al. 2012. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J. Mol. Cell. Cardiol. 52:1299-1307. http://dx.doi.org/10.1016/j.yjmcc.2012.03.009
18. Gao, W.D., Y. Liu, and E. Marban. 1996. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation. 94:2597-2604. http://dx.doi.org/10.1161/01.CIR.94.10.2597
19. Gautel, M., O. Zuffardi, A. Freiburg, and S. Labeit. 1995. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J. 14:1952-1960.
20. Govada, L., L. Carpenter, P.C. da Fonseca, J.R. Helliwell, P. Rizkallah, E. Flashman, N.E. Chayen, C. Redwood, and J.M. Squire. 2008. Crystal structure of the C1 domain of cardiac myosin binding protein-C: implications for hypertrophic cardiomyopathy. J. Mol. Biol. 378:387-397. http://dx.doi.org/10.1016/j.jmb.2008.02.044
21. Gruen, M., and M. Gautel. 1999. Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy(FHC) abolish the interaction with the regulatory domain of myosin-binding protein- C. J. Mol. Biol. 286:933-949. http://dx.doi.org/10.1006/jmbi.1998.2522
22. Gruen, M., H. Prinz, and M. Gautel. 1999. cAPK-phosphorylation controls the interaction of the regulatory domain of cardiac myosin binding protein C with myosin-S2 in an on-offfashion. FEBS Lett. 453:254-259. http://dx.doi.org/10.1016/S0014-5793(99)00727-9
23. Harris, S.P., C.R. Bartley, T.A. Hacker, K.S. McDonald, P.S. Douglas, M.L. Greaser, P.A. Powers, and R.L. Moss. 2002. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ. Res. 90:594-601. http://dx.doi.org/10.1161/01.RES.0000012222.70819.64
24. Hiranandani, N., K.D. Varian, M.M. Monasky, and P.M.L. Janssen. 2006. Frequency-dependent contractile response of isolated cardiac trabeculae under hypo-, normo-, and hyperthermic conditions. J. Appl. Physiol. 100:1727-1732. http://dx.doi.org/10.1152/japplphysiol.01244.2005
25. Hofmann, P.A., M.L. Greaser, and R.L. Moss. 1991. C-protein limits shortening velocity of rabbit skeletal muscle fibres at low levels of Ca2+ activation. J. Physiol. 439:701-715.
26. Kensler, R.W., J.F. Shaffer, and S.P. Harris. 2011. Binding of the N-terminal fragment C0-C2 of cardiac MyBP-C to cardiac F-actin. J. Struct. Biol. 174:44-51. http://dx.doi.org/10.1016/j.jsb.2010.12.003
27. Korte, F.S., K.S. McDonald, S.P. Harris, and R.L. Moss. 2003. Loaded shortening, power output, and rate of force redevelopment are increased with knockout of cardiac myosin binding protein-C. Circ. Res. 93:752-758. http://dx.doi.org/10.1161/01.RES.0000096363.85588.9A
28. Lu, Y., A.H. Kwan, J. Trewhella, and C.M. Jeffries. 2011. The C0C1 fragment of human cardiac myosin binding protein C has common binding determinants for both actin and myosin. J. Mol. Biol. 413:908-913. http://dx.doi.org/10.1016/j.jmb.2011.09.026
29. Maron, B.J., J.M. Gardin, J.M. Flack, S.S. Gidding, T.T. Kurosaki, and D.E. Bild. 1995. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in(Young) Adults. Circulation. 92:785-789. http://dx.doi.org/10.1161/01.CIR.92.4.785
30. arston, S., O. Copeland, A. Jacques, K. Livesey, V. Tsang, W.J. McKenna, S. Jalilzadeh, S. Carballo, C. Redwood, and H. Watkins. 2009. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ. Res. 105:219-222. http://dx.doi.org/10.1161/CIRCRESAHA.109.202440
31. Marston, S., O. Copeland, K. Gehmlich, S. Schlossarek, and L. Carrier. 2012. How do MYBPC3 mutations cause hypertrophic cardiomyopathy. J. Muscle Res. Cell Motil. 33:75-80.(published erratum appears in J. Muscle Res. Cell Motil. 2012. 33:81) http://dx.doi.org/10.1007/s10974-011-9268-3
32. McDonald, K.S., M.R. Wolff, and R.L. Moss. 1998. Force-velocity and power-load curves in rat skinned cardiac myocytes. J. Physiol. 511:519-531. http://dx.doi.org/10.1111/j.1469-7793.1998.519bh.x
33. Morita, H., H.L. Rehm, A. Menesses, B. McDonough, A.E. Roberts, R. Kucherlapati, J.A. Towbin, J.G. Seidman, and C.E. Seidman. 2008. Shared genetic causes of cardiac hypertrophy in children and adults. N. Engl. J. Med. 358:1899-1908. http://dx.doi.org/10.1056/NEJMoa075463
34. Nanni, L., M. Pieroni, C. Chimenti, B. Simionati, R. Zimbello, A. Maseri, A. Frustaci, and G. Lanfranchi. 2003. Hypertrophic cardiomyopathy: two homozygous cases with "typical" hypertrophic cardiomyopathy and three new mutations in cases with progression to dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 309:391-398. http://dx.doi.org/10.1016/j.bbrc.2003.08.014
35. Niimura, H., L.L. Bachinski, S. Sangwatanaroj, H. Watkins, A.E. Chudley, W. McKenna, A. Kristinsson, R. Roberts, M. Sole, B.J. Maron, et al. 21998. Mutations in the gene for cardiac myosin- binding protein C and late-onset familial hypertrophic cardiomyopathy. N. Engl. J. Med. 338:1248-1257. http://dx.doi
36. livotto, I., F. Girolami, M.J. Ackerman, S. Nistri, J.M. Bos, E. Zachara, S.R. Ommen, J.L. Theis, R.A. Vaubel, F. Re, et al. 2008. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin. Proc. 83:630-638.
37. Page, S.P., S. Kounas, P. Syrris, M. Christiansen, R. Frank-Hansen, P.S. Andersen, P.M. Elliott, and W.J. McKenna. 2012. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Circ. Cardiovasc. Genet. 5:156-166. http://dx.doi.org/10.1161/CIRCGENETICS.111.960831
38. Razumova, M.V., J.F. Shaffer, A.Y. Tu, G.V. Flint, M. Regnier, and S.P. Harris. 2006. Effects of the N-terminal domains of myosin binding protein-C in an in vitro motility assay: Evidence for longlived cross-bridges. J. Biol. Chem. 281:35846-35854. http://dx.doi.org/10.1074/jbc.M606949200
39. Richard, P., P. Charron, L. Carrier, C. Ledeuil, T. Cheav, C. Pichereau, A. Benaiche, R. Isnard, O. Dubourg, M. Burban, et al. 2003. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 107:2227-2232. http://dx.doi.org/10.1161/01.CIR.0000066323.15244.54
40. Rybakova, I.N., M.L. Greaser, and R.L. Moss. 2011. Myosin binding protein C interaction with actin: characterization and mapping of the binding site. J. Biol. Chem. 286:2008-2016. http://dx.doi.org/10.1074/jbc.M110.170605
41. Sadayappan, S., J. Gulick, H. Osinska, D. Barefield, F. Cuello, M. Avkiran, V.M. Lasko, J.N. Lorenz, M. Maillet, J.L. Martin, et al. 2011. A critical function for Ser-282 in cardiac Myosin binding protein-C phosphorylation and cardiac function. Circ. Res. 109: 141-150. http://dx.doi.org/10.1161/CIRCRESAHA.111.242560
42. Seidman, J.G., and C. Seidman. 2001. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 104:557-567. http://dx.doi.org/10.1016/S0092-8674(01)00242-2
43. Shaffer, J.F., R.W. Kensler, and S.P. Harris. 2009. The myosinbinding protein C motif binds to F-actin in a phosphorylationsensitive manner. J. Biol. Chem. 284:12318-12327. http://dx.doi.org/10.1074/jbc.M808850200
44. Song, L., Y. Zou, J. Wang, Z. Wang, Y. Zhen, K. Lou, Q. Zhang, X. Wang, H. Wang, J. Li, and R. Hui. 2005. Mutations profile in Chinese patients with hypertrophic cardiomyopathy. Clin. Chim. Acta. 351:209-216. http://dx.doi.org/10.1016/j.cccn.2004.09.016
45. Spirito, P., C.E. Seidman, W.J. McKenna, and B.J. Maron. 1997. The management of hypertrophic cardiomyopathy. N. Engl. J. Med. 336:775-785. http://dx.doi.org/10.1056/NEJM199703133361107
46. Tobita, K., L.J. Liu, A.M. Janczewski, J.P. Tinney, J.M. Nonemaker, S. Augustine, D.B. Stolz, S.G. Shroff, and B.B. Keller. 2006. Engineered early embryonic cardiac tissue retains proliferative and contractile properties of developing embryonic myocardium. Am. J. Physiol. Heart Circ. Physiol. 291:H1829-H1837. http://dx.doi.org/10.1152/ajpheart.00205.2006
47. van Dijk, S.J., D. Dooijes, C. dos Remedios, M. Michels, J.M. Lamers, S. Winegrad, S. Schlossarek, L. Carrier, F.J. ten Cate, G.J. Stienen, and J. van der Velden. 2009. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 119:1473-1483. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.838672
48. Van Driest, S.L., V.C. Vasile, S.R. Ommen, M.L. Will, A.J. Tajik, B.J. Gersh, and M.J. Ackerman. 2004. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44:1903-1910. http://dx.doi.org/10.1016/j.jacc.2004.07.045
49. Vignier, N., S. Schlossarek, B. Fraysse, G. Mearini, E. Krämer, H. Pointu, N. Mougenot, J. Guiard, R. Reimer, H. Hohenberg, et al. 2009. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ. Res. 105:239-248. http://dx.doi.org/10.1161/CIRCRESAHA.109.201251
50. Weisberg, A., and S. Winegrad. 1996. Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle. Proc. Natl. Acad. Sci. USA. 93:8999-9003. http://dx.doi.org/10.1073/pnas.93.17.8999